New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis
ROCKVILLE, Md. & EDMONTON, Alberta — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced that a post-hoc analysis of the 52-week, Phase 3 AURORA 1 study showed that lupus nephritis (LN) patients who received triple immunosuppressive therapy with LUPKYNIS ® (voclosporin), mycophenolate mofetil (MMF), and low-dose glucocorticoids achieved lower proteinuria targets at substantially higher rates compared to patients in the control group who received mycophenolate mofetil (MMF) and low-dose glucocorticoids alone.
Article content
The analysis assessed the achievement of urine protein creatine ratio (UPCR) targets of ≤0.4 g/g, ≤0.3 g/g, ≤0.2 g/g (classified as ultra-low UPCR), and ≤0.1 g/g in LN patients treated with LUPKYNIS-based triple immunosuppressive therapy compared to patients in the control group. Of the 357 patients in AURORA 1, 60.9% in the triple immunosuppressive therapy group (N=109) achieved a UPCR of ≤0.4 g/g at least once during the study compared to 37.1% of patients in the control group (N=66). Patients in the triple immunosuppressive therapy group also achieved higher rates of all other UPCR targets compared to patients in the control group. Adverse event rates were comparable in both groups.
Article content
'It is widely known that no level of proteinuria is safe for nephrons and that early reductions in proteinuria are predictive of better long-term kidney outcomes. Yet, UPCR endpoints have varied widely across clinical trials and in clinical practice,' said lead study author Maria Dall'Era, M.D., Professor of Medicine in the Division of Rheumatology, University of California, San Francisco. 'This analysis shows that achieving UPCR targets of ≤0.4 g/g may be a feasible goal and that a voclosporin-based triple immunosuppressive therapy regimen can reduce proteinuria to profoundly low levels in a proportion of patients.'
Article content
An additional post-hoc analysis from the AURORA 1 study evaluated lipidomic profiles in LN patients based on achievement of proteinuria reductions, including ultra-low UPCR, at Week 52. The analysis found a distinct lipidomic profile in patients who achieved ultra-low UPCR. This analysis builds upon a previous analysis of AURORA 1 in which patients who received triple immunosuppressive therapy with LUPKYNIS achieved significantly greater improvements in total and low-density lipoprotein (LDL) cholesterol compared to those in the control group. While further research is needed to clarify the role of certain lipids in the biochemistry of LN patients, these preliminary findings suggest that attaining ultra-low UPCR targets may provide additional benefits to LN patients and contribute to modification of cardiovascular disease risk.
Article content
An analysis of real-world baseline data from ENLIGHT-LN, a U.S.-based prospective, observational registry of adult LN patients treated with LUPKYNIS, was also presented at LUPUS 2025.
'The data presented at LUPUS 2025 highlight the critical role of LUPKYNIS in improving health outcomes for LN patients. Early reduction of proteinuria to the lowest possible levels and long-term preservation of kidney health are key goals of LN therapy. These data provide compelling evidence that LUPKYNIS-based therapy can achieve significantly lower UPCR targets, potentially reducing the risk of significant kidney damage and other comorbidities,' said Dr. Greg Keenan, Chief Medical Officer of Aurinia.
Article content
Title: Attainment of Ultra-Low Levels of UPCR in the AURORA 1 Study Associated with Alterations in the Circulating Lipidome
Authors: Farsad Afshinnia, Subramaniam Pennathur, Michelle Zubrycki, Linda Rehaume, Lucy Hodge
Date: Thursday, May 22
Time: 12:10 – 1:10 PM ET
Abstract Number: 252
Article content
About LUPKYNIS
Article content
LUPKYNIS is a second generation calcineurin inhibitor with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production and promoting podocyte stability in the kidney. The AURORA Clinical Program, comprised of the AURORA 1 pivotal trial and AURORA 2 extension trial, demonstrated the importance of triple immunosuppressive therapy with LUPKYNIS, mycophenolate mofetil, and low-dose glucocorticoids to preserve kidney health in lupus nephritis patients without reliance on chronic high-dose glucocorticoids. It is the only clinical program in lupus nephritis to include three years of triple immunosuppressive therapy.
Article content
About Aurinia
Article content
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand).
Article content
LUPKYNIS is indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN).
Article content
Limitations of Use: Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation.
Article content
CONTRAINDICATIONS: LUPKYNIS is contraindicated in patients taking strong CYP3A4 inhibitors because of the increased risk of acute and/or chronic nephrotoxicity, and in patients who have had a serious/severe hypersensitivity reaction to LUPKYNIS or its excipients.
Article content
WARNINGS AND PRECAUTIONS
Article content
Lymphoma and Other Malignancies: Immunosuppressants, including LUPKYNIS, increase the risk of developing lymphomas and other malignancies, particularly of the skin. The risk appears to be related to increasing doses and duration of immunosuppression rather than to the use of any specific agent.
Article content
Serious Infections: Immunosuppressants, including LUPKYNIS, increase the risk of developing bacterial, viral, fungal, and protozoal infections, including opportunistic infections. These infections may lead to serious, including fatal, outcomes.
Article content
Nephrotoxicity: LUPKYNIS, like other calcineurin inhibitors (CNIs), may cause acute and/or chronic nephrotoxicity. The risk is increased when CNIs are concomitantly administered with drugs associated with nephrotoxicity. Monitor eGFR regularly.
Article content
Hypertension: Hypertension is a common adverse reaction of LUPKYNIS therapy and may require antihypertensive therapy. Monitor blood pressure regularly.
Article content
Neurotoxicity: LUPKYNIS, like other CNIs, may cause a spectrum of neurotoxicities: severe include posterior reversible encephalopathy syndrome (PRES), delirium, seizure, and coma; others include tremor, paresthesia, headache, and changes in mental status and/or motor and sensory functions. Monitor for neurologic symptoms.
Article content
Hyperkalemia: Hyperkalemia, which may be serious and require treatment, has been reported with CNIs, including LUPKYNIS. Concomitant use of agents associated with hyperkalemia may increase the risk for hyperkalemia. Monitor serum potassium levels periodically.
Article content
QTc Prolongation: LUPKYNIS prolongs the QTc interval in a dose-dependent manner when dosed higher than the recommended lupus nephritis therapeutic dose. The use of LUPKYNIS in combination with other drugs that are known to prolong QTc may result in clinically significant QT prolongation.
Article content
Immunizations: Avoid the use of live attenuated vaccines during treatment with LUPKYNIS. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment with LUPKYNIS.
Article content
Pure Red Cell Aplasia: Cases of pure red cell aplasia (PRCA) have been reported in patients treated with another CNI immunosuppressant. If PRCA is diagnosed, consider discontinuation of LUPKYNIS.
Article content
Drug-Drug Interactions: Avoid co-administration of LUPKYNIS and strong CYP3A4 inhibitors or with strong or moderate CYP3A4 inducers. Co-administration of LUPKYNIS with strong CYP3A4 inhibitors is contraindicated. Reduce LUPKYNIS dosage when co-administered with moderate CYP3A4 inhibitors. Avoid use of LUPKYNIS with strong or moderate CYP3A4 inducers.
Article content
ADVERSE REACTIONS
Article content
The most common adverse reactions (≥3%) were glomerular filtration rate decreased, hypertension, diarrhea, headache, anemia, cough, urinary tract infection, abdominal pain upper, dyspepsia, alopecia, renal impairment, abdominal pain, mouth ulceration, fatigue, tremor, acute kidney injury, and decreased appetite.
Article content
SPECIFIC POPULATIONS
Article content
Pregnancy: Avoid use of LUPKYNIS.
Article content
Lactation: Consider the mother's clinical need for LUPKYNIS and any potential adverse effects to the breastfed infant when prescribing LUPKYNIS to a lactating woman.
Article content
Renal Impairment: LUPKYNIS is not recommended in patients with baseline eGFR ≤45 mL/min/1.73 m 2 unless benefit exceeds risk. If used in this population, reduce LUPKYNIS dose.
Article content
Dall'Era M. et al. Achievement of Proteinuria Less Than 0.4 G/G in the Phase 3 AURORA 1 Study of Voclosporin in Lupus Nephritis. Presented at LUPUS 2025 Congress, 2025, Toronto, CA.
Geraldino-Pardilla L. et al. Baseline Demographics, Clinical Characteristics, and Treatment Regimens of an Initial Cohort of Patients Receiving Voclosporin for Lupus Nephritis in the Enlight-LN Registry. Presented at LUPUS 2025 Congress, 2025, Toronto, CA.
Afshinnia F. et al. Attainment of Ultra-Low Levels of UPCR in the AURORA 1 Study Associated with Alterations in the Circulating Lipidome. Presented at LUPUS 2025 Congress, 2025, Toronto, CA.
Arriens C. et al. Arthritis Care & Research. Vol. 75, No. 7, July 2023, pp 1399–1408.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
34 minutes ago
- CBC
What health experts are saying about Alberta's COVID-19 vaccination program
Social Sharing Health experts, advocates and unions are sounding the alarm over Alberta's plan for paid COVID-19 shots, calling it concerning and confusing. On Monday, two months after the province announced it was adding a fee, it opened online pre-ordering for the vaccine. Albertans still need to book appointments for the shots, starting in October. Dr. James Talbot, the province's former chief medical officer of health, said the government appears to be doing everything it can to make this year's immunization campaign a "failure" by making it less available, less accessible and less affordable. "They are basically sabotaging their own COVID campaign," he said. He's among a chorus of critics warning it could lead to more hospitalizations and stress on the health-care system. Talbot and other public health experts and physicians penned an opinion piece in the Edmonton Journal last week, arguing the plan creates unfair barriers and puts Albertans at risk. "You've created this unfairness where if you're rich, you can get protected, but if you're poor, you may not be able to," Talbot said. Leigh Allard, president and CEO of Alberta Lung, part of the National Lung Health Alliance, said the government's policy makes it an extreme outlier and its precedent could ripple across the country. Those who suffer from lung conditions like asthma, cystic fibrosis or pulmonary fibrosis are vulnerable, she added. This year, Albertans also won't be able to walk into a pharmacy to get a COVID-19 shot, where the vast majority of doses were given last year. They must go to a public health clinic. Allard said people are confused over the plan. She's also concerned many won't be able to access a clinic for a shot, especially if hours aren't extended, or some simply won't be able to afford it. She said she expects an uptake in Alberta Lung's financial assistance programs. "As a charity, we should not be supplementing what the government should be doing." The government said it will still pay for some to get shots, including those who have compromised immune systems or are on social programs. Seniors in congregate settings will also be covered. However, the specifics of the qualifying health conditions have not been released. It's estimated a shot could cost $110, but the government has yet to pin down the price. Kyle Warner, spokesperson for Primary and Preventative Health Minister Adriana LaGrange, said details are forthcoming. "The fall immunization plan is being finalized, and details — including the updated vaccination schedule, eligible conditions, exact locations and administrative fee for COVID-19 vaccines — will be available soon," he said in a statement. Warner also said Albertans who don't pre-order by the Sept. 30 deadline can still book a vaccine appointment once doses become available. He said online pre-ordering helps determine future vaccine needs, minimize waste, manage delivery and prevent double bookings, since the influenza vaccine can be given at the same time. Those who pre-order are promised a reminder in October to book an appointment. The province said it has ordered 485,000 doses of COVID-19 vaccine for the fall and some of the estimated $49-million cost would be covered through those who have to pay. The government didn't respond to questions about whether it has a contingency plan to order more doses if needed, whether out-of-province costs might be reimbursed, and what informed its decision to order 250,000 fewer doses than last year. It also didn't clarify whether flu shots, which remain free, would be available in pharmacies. The province's interim chief medical officer of health, Dr. Sunil Sookram, wasn't made available for an interview. Talbot called withholding the specifics disrespectful. "It's bad enough that there's a list that says you're going to ration it, but then to have confusion about who's on the list — that just seems cruel," he said. The province has said an estimated one million COVID-19 vaccine doses, or just over half of Alberta's supply, weren't used during the 2023-24 respiratory virus season. Premier Danielle Smith has said that meant $135 million was "flushed down the drain." Facing heated questions about the policy at a public town hall in Edmonton on Thursday, Smith said her United Conservative Party government is trying not to waste public money. "There are lots of different types of vaccines that are paid for out of pocket right now ... because the federal government defunded it," she said, pointing to shots for yellow fever, which also need to be purchased. The latest provincial data says 394 Albertans with confirmed COVID-19 have died since last August. Talbot and labour leaders have also said the plan puts health workers in harm's way, and potentially forces those in an already strained system to take sick time off work to avoid infecting others. "You're going to be the only province in the country that says we care so little about these people that we're going to force them to pay for their own vaccine," said Talbot. "It seems inconceivable to me that a rational mind would think that was a good way to recruit and retain health-care professionals." Unions warned this week of potential fallout. In a Tuesday letter to the premier, Alberta Federation of Labour president Gil McGowan wrote it would be a violation of workplace health and safety laws not to include all health workers, education workers, transit operators and those in the service sector on its priority list. McGowan said he's also hearing frustration and confusion from front-line members. "It's not just incompetence. This is clearly not a vaccine rollout strategy. It's a vaccine suppression strategy," he said. The United Nurses of Alberta has said the plan limits the freedom of Albertans to choose vaccination by intentionally limiting supply and penalizing those who can't afford it.
National Post
35 minutes ago
- National Post
Lawyer insists foreign adversary is behind Canadian diplomats' Havana Syndrome
Article content The Global Affairs report traces the various steps federal agencies have taken over the years in response to the illness complaints, including security, medical and environmental assessments. Article content A multi-agency Integrated National Security Enforcement Team, led by the RCMP, opened an investigation in June 2017. Article content Global Affairs and RCMP officials began travelling regularly to Cuba as part of the investigation to look at the possibility of malicious attacks, the report says. Canadian officials also shared information with foreign partners, including the United States. Article content In 2019, instruments designed to detect and capture evidence of acoustic and radiation surges, and to measure environmental effects — such as temperature, humidity, barometric pressure and ozone levels — were installed in the living quarters of Canadian staff in Havana. Article content 'The data collected from the instruments did not provide relevant and probative information to identify a cause for the symptoms,' the Global Affairs report says. 'As such, in 2022, the instruments were removed.' Article content Article content The integrated national security team concluded 'there was no criminality and no evidence attributing these health symptoms to a foreign actor,' the report adds. Article content 'In their conclusions, the RCMP and other domestic partner agencies assess that there is no known criminality, no known attribution for (unexplained health incidents) and no patterns related to symptoms, age, gender, location, or other variable.' Article content The U.S. intelligence community looked at possible evidence of a foreign adversary's involvement, the feasibility of tools that could cause the reported symptoms and whether medical analysis could help find answers. Article content A March 1, 2023, report from the U.S. National Intelligence Council said these lines of inquiry led most intelligence community agencies to conclude — with varying levels of confidence — that it was 'very unlikely' a foreign adversary was responsible for the health issues reported by American personnel. Article content Global Affairs, the Canadian Security Intelligence Service and the RCMP subsequently met to discuss the U.S. council's findings. Article content Article content The RCMP indicated that 'since no criminality was uncovered, its criminal investigation would be concluded,' and CSIS advised it also would be wrapping up its investigations for similar reasons, the Global Affairs report says. Article content Overall, the Canadian efforts 'have not uncovered a clear common cause of the symptoms experienced by government of Canada employees,' the report adds. 'Canada's findings are aligned with the conclusions of the United States on their various health studies and the security report published by the National Intelligence Council.' Article content Miller points to other research and testimony that challenge those findings. Article content Lawyer Mark Zaid, representing several U.S. personnel with symptoms, told a congressional hearing in May 2024 that there was intelligence, scientific and medical evidence substantiating the reports of anomalous health incidents, and that some were caused by a foreign adversary. Article content Zaid, who had authorized access to secret details, said he was convinced that 'the evidence that exists in the classified arena directly contradicts the public conclusions' provided by U.S. federal agencies about the cause of the health symptoms.
CBC
2 hours ago
- CBC
Staffing shortages prompt closure of LifeLabs location in Thunder Bay, Ont., until October
One of three LifeLabs clinics in Thunder Bay, Ont., is closed until October due to staffing shortages. The Port Arthur Health Centre posted on Facebook Aug. 9 that the LifeLabs Medical Laboratory Services facility within its building would be closed through the end of September. "Like many health-care providers across the country, we are experiencing staffing challenges. As a result, we have made the decision to temporarily close this location to ensure we can resume operations safely and effectively," a spokesperson for LifeLabs wrote in an email to CBC News on Friday. "Our priority is to maintain the highest standards of care and safety for our patients." The Port Arthur location is expected to reopen on Oct. 1, LifeLabs says. The two remaining LifeLabs in the northwestern Ontario city are located at 1040 Oliver Rd., near Lakehead University, and 1265 Arthur St E., on the city's south side. Dr. Sarah Newbery is a rural generalist family physician based in Marathon, as well as the associate dean of physician workforce strategy at Northern Ontario School of Medicine (NOSM) University. In smaller communities in the region where there are no private lab clinics, such as Marathon, Manitouwadge and Terrace Bay, all lab testing is done through hospitals, she said. "One of the challenges is that options can be limited, hours can sometimes be limited," Newbery said. "On the plus side, because lab services are so crucial to the way in which hospitals function, keeping those lab services open is really important and I think provides a really helpful service for community-based lab access as well." For those who are used to going to private clinics, having to go elsewhere may lead them to postpone their testing, she said. "As soon as we ask people to travel for something, even if it's across town, even if it's just a simple taxi ride away, that puts up a small barrier for some people to being able to get those services," Newbery said. "Any time we put up a barrier to accessing services, we run the risk that people won't actually be able to follow through on that and that their health and their health outcomes may be impacted by that." Having as many medical services as possible under the same roof helps to eliminate those barriers, she said, and means people will be more likely to get testing done. Any time we put up a barrier to accessing services, we run the risk that people won't actually be able to follow through on that and that their health and their health outcomes may be impacted by that. While LifeLabs did not specify the nature of the staffing shortages in Thunder Bay, Newbery said there's been ongoing challenges with a lack of medical lab technicians across the region. "I think the more that we can support the health human resources that we need to ensure the sustainability of services, the better off access to services in the north will be," she said. "Looking at how we might incent people to be able to stay — particularly working in our hospital environments but in all of the lab facility environments in northern Ontario — feels important to those health human resources." Her advice for those left scrambling is to consult with their physician or nurse practitioner about the urgency of their testing. "Being clear about the expectation of timing, getting those tests done, is important — and then trying to work out where the nearest place that you can get that done in as convenient a way as possible is important," Newbery said.
